TY - JOUR
T1 - A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib
AU - McWeeney, Shannon K.
AU - Pemberton, Lucy C.
AU - Loriaux, Marc M.
AU - Vartanian, Kristina
AU - Willis, Stephanie G.
AU - Yochum, Gregory
AU - Wilmot, Beth
AU - Turpaz, Yaron
AU - Pillai, Raji
AU - Druker, Brian J.
AU - Snead, Jennifer L.
AU - MacPartlin, Mary
AU - O'Brien, Stephen G.
AU - Melo, Junia V.
AU - Lange, Thoralf
AU - Harrington, Christina A.
AU - Deininger, Michael W.N.
PY - 2010/1/14
Y1 - 2010/1/14
N2 - In chronic-phase chronic myeloid leukemia (CML) patients, the lack of a major cytogenetic response (< 36% Ph+ metaphases) to imatinib within 12 months indicates failure and mandates a change of therapy. To identify biomarkers predictive of imatinib failure, we performed gene expression array profiling of CD34+ cells from 2 independent cohorts of imatinib-naive chronic-phase CML patients. The learning set consisted of retrospectively selected patients with a complete cytogenetic response or more than65%Ph + metaphases within 12 months of imatinib therapy.Basedonanalysis of varianceP less than .1 and fold difference 1.5 or more, we identified 885 probe sets with differential expression between responders and nonre-sponders, from which we extracted a 75-probe set minimal signature (classifier) that separated the 2 groups. On application to a prospectively accrued validation set, the classifier correctly predicted 88% of responders and83% of nonresponders. Bioinformatics analysis and comparison with published studies revealed overlap of classifier genes withCMLprogression signatures and implicated β-catenin in their regulation, suggesting that chronic-phase CML patients destined to fail imatinib have more advanced disease than evident by morphologic criteria. Our classifier may allow directing more aggressive therapy upfront to the patients most likely to benefit while sparing good-risk patients from unnecessary toxicity.
AB - In chronic-phase chronic myeloid leukemia (CML) patients, the lack of a major cytogenetic response (< 36% Ph+ metaphases) to imatinib within 12 months indicates failure and mandates a change of therapy. To identify biomarkers predictive of imatinib failure, we performed gene expression array profiling of CD34+ cells from 2 independent cohorts of imatinib-naive chronic-phase CML patients. The learning set consisted of retrospectively selected patients with a complete cytogenetic response or more than65%Ph + metaphases within 12 months of imatinib therapy.Basedonanalysis of varianceP less than .1 and fold difference 1.5 or more, we identified 885 probe sets with differential expression between responders and nonre-sponders, from which we extracted a 75-probe set minimal signature (classifier) that separated the 2 groups. On application to a prospectively accrued validation set, the classifier correctly predicted 88% of responders and83% of nonresponders. Bioinformatics analysis and comparison with published studies revealed overlap of classifier genes withCMLprogression signatures and implicated β-catenin in their regulation, suggesting that chronic-phase CML patients destined to fail imatinib have more advanced disease than evident by morphologic criteria. Our classifier may allow directing more aggressive therapy upfront to the patients most likely to benefit while sparing good-risk patients from unnecessary toxicity.
UR - http://www.scopus.com/inward/record.url?scp=75649084233&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=75649084233&partnerID=8YFLogxK
U2 - 10.1182/blood-2009-03-210732
DO - 10.1182/blood-2009-03-210732
M3 - Article
C2 - 19837975
AN - SCOPUS:75649084233
SN - 0006-4971
VL - 115
SP - 315
EP - 325
JO - Blood
JF - Blood
IS - 2
ER -